Clinical Trials Logo

Clinical Trial Summary

The primary purpose of the study is to evaluate safety and tolerability and to determine recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part, and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in Phase 2 part in each tumor type.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04078295
Study type Interventional
Source Eisai Inc.
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date September 5, 2019
Completion date January 31, 2024

See also
  Status Clinical Trial Phase
Withdrawn NCT02896049 - Celsius TCS Hyperthermia System PMCF Trial
Active, not recruiting NCT03833700 - A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) Phase 1
Recruiting NCT04407676 - Improving Informed Consent for Early Phase Anti-Cancer Trials N/A
Recruiting NCT04420884 - A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03364049 - Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) Phase 1
Completed NCT01543282 - Endoscopic Ultrasonography (EUS) Guided Fine Needle Aspiration Using Free Stylet 22g and 25 g Needles N/A